体外研究 (In Vitro) |
Disobutamide (1×10-4-10×10-4 M; 24 h) 不会对大鼠膀胱癌细胞或兔主动脉肌细胞产生显著细胞毒性 (以 LDH 释放为检测指标),但在 ≥4×10-4 M 浓度下,会对大鼠嗜碱性白血病细胞产生严重细胞毒性。 Disobutamide (10-3 M; 24 h) 在大鼠膀胱癌细胞 (RBT CC-8) 中的细胞摄取量会随培养基碱性增强而提升,摄取水平较高时会形成明显的细胞质空泡。 Disobutamide (10-6-10-3 M; 30 min-6 hr) 表现出种属特异性的体外脉络丛组织摄取,其中大鼠脉络丛的摄取量最高,其次是猴脉络丛,然后是犬脉络丛;且在 ≥10-4 M 时可诱导犬脉络丛上皮细胞呈剂量依赖性空泡化。
Cell Cytotoxicity Assay
| Cell Line: |
rat urinary bladder carcinoma (RBT CC-8) cells, rabbit aorta muscle cells, rat basophilic leukaemia cells |
| Concentration: |
1×10-4 M, 2×10-4 M, 4×10-4 M, 6×10-4 M, 8×10-4 M, 10×10-4 M |
| Incubation Time: |
24 h |
| Result: |
Caused LDH release relative to total enzyme of ≤5.2% at all tested concentrations in rat urinary bladder carcinoma cells. Caused LDH release relative to total enzyme ranging from 5.3% at 1×10-4 M to 31.2% at 10×10-4 M in rabbit aorta muscle cells, a magnitude not indicative of cytotoxicity. Caused LDH release relative to total enzyme of 2.2% at 1×10-4 M, 18.7% at 2×10-4 M, and 84.4-89.9% at 4×10-4 M to 10×10-4 M in rat basophilic leukaemia cells, indicating significant cytotoxicity at concentrations ≥4×10-4 M. |
|
体内研究 (In Vivo) |
Disobutamide (6-90 mg/kg/天;口服;每日;14 天-52 周) 可在犬的多种细胞类型和器官中诱导呈剂量/时间依赖性的进行性胞质空泡化,且无明显细胞损伤;同时,高慢性剂量下会引发心脏电生理效应和猝死,而绒毡层改变的未观察到不良反应阈值低于 6 mg/kg/day。 Disobutamide (10-300 mg/kg/天;口服;每日给药;5 天-52 周) 在 300 mg/kg/天剂量下可诱导褐家鼠脉络丛和附睾上皮细胞出现选择性胞质空泡化,相同剂量下长期暴露会引发致死性毒性,且在长期高剂量给药过程中可诱导肝磷脂沉积但无细胞损伤。 Disobutamide (30-250 mg/kg;灌胃;每日;4-35 天) 可在大鼠多个器官中诱导剂量依赖性溶酶体空泡化 (磷脂沉积症),其中 250 mg/kg 剂量下脉络丛上皮空泡化程度极重,100 mg/kg 剂量下为中度改变,30 mg/kg 剂量下为轻度改变。 Disobutamide (45 mg/kg;口服;每日一次;连续 35 天) 会在犬类的多个器官中诱导空泡形成,但不会影响脉络丛上皮细胞;而直接脑室内给药 (0.035 mg;脑室内注射;单次) 会引发脉络丛上皮细胞空泡形成,这与口服给药时药物难以穿透进入脑脊液 (CSF) 有关。 Disobutamide (90 mg/kg;灌胃;每日;35 天) 会引发猕猴脉络丛上皮细胞极为严重的空泡化,以及其他器官的剂量依赖性空泡化,这与脉络丛中药物浓度较高、且脑脊液/血清比值随时间升高相关。
| Animal Model: |
Jcl:SD rats (male and female, 5 weeks of age) |
| Dosage: |
30 mg/kg; 100 mg/kg; 250 mg/kg |
| Administration: |
i.g.; daily; 13 weeks (30, 100, 250 mg/kg); i.g.; single dose (100, 250 mg/kg); i.g.; daily; 4, 7, or 35 days (100, 250 mg/kg) |
| Result: |
Caused 10/16 males and 10/16 females to die of convulsions during weeks 1-9 at 250 mg/kg. Reduced feed intake and depressed body weight gain in both sexes at 250 mg/kg. Elevated total cholesterol in both sexes, phospholipid in males, and triglyceride in females at 250 mg/kg. Decreased most organ weights in males, and thymus/spleen weights in females at 250 mg/kg. Induced very severe vacuolation in choroid plexus epithelium, severe vacuolation in renal distal tubules and hepatocytes, moderate vacuolation in submaxillary gland, bronchus, uterine epithelium, cardiac muscle, coronary artery, and lung macrophages, slight vacuolation in stomach, small intestine, spleen macrophages, thymus macrophages, and bone marrow macrophages at 250 mg/kg. Detected choroid plexus drug concentration of 11.8 mg/g, brain concentration of 26.2 μg/g, liver concentration of 604 μg/g, and kidney concentration of 403 μg/g after 35 days of 250 mg/kg dosing. Caused muscle relaxation and prone position in females, slight feed intake decrease and body weight gain depression in males, slight thymus weight decrease in males, and slight vacuolation in submaxillary gland, bronchus, cardiac muscle, coronary artery, lung macrophages, thymus macrophages, and bone marrow macrophages at 100 mg/kg. Induced large lysosome increase in choroid plexus epithelium after 4 days and vacuoles in large choroid plexus lysosomes after 7 days of 100 mg/kg dosing. Caused slight thymus weight decrease in males and slight vacuolation in submaxillary gland, cardiac muscle, coronary artery, thymus macrophages, and bone marrow macrophages at 30 mg/kg. |
| Animal Model: |
Beagle dogs (female, 13-17 months of age; male and female, 10 months of age) |
| Dosage: |
45 mg/kg; 0.035 mg total dose |
| Administration: |
p.o.; daily; 35 days (45 mg/kg); i.c.v.; single dose (0.035 mg) |
| Result: |
Induced severe vacuolation in stomach, small intestine, renal distal tubules, and bronchial epithelium, moderate vacuolation in spleen macrophages, slight vacuolation in esophagus, submaxillary gland, iris pigment epithelium, hepatocytes, cardiac muscle, coronary artery, aorta, intestinal muscle cells, lung macrophages, thymus macrophages, and bone marrow macrophages at 45 mg/kg p.o. Detected choroid plexus drug concentration of 0.124 mg/g, brain concentration of 12.2 μg/g, liver concentration of 468 μg/g, and kidney concentration of 653 μg/g after 35 days of 45 mg/kg p.o. dosing. Caused numerous enlarged lysosomes (some with vacuoles) in choroid plexus epithelial cells 3 hours after 0.035 mg i.c.v. dosing. |
| Animal Model: |
Macaca fasciculata (female, adult age) |
| Dosage: |
90 mg/kg |
| Administration: |
i.g.; daily; 35 days |
| Result: |
Induced severe lymphocyte cytoplasmic vacuolation; one monkey showed elevated total cholesterol and phospholipid at 2 weeks. Caused very severe vacuolation in choroid plexus epithelium, severe vacuolation in renal distal tubules and intestinal muscle cells, moderate vacuolation in stomach, small intestine, bronchial epithelium, uterine epithelium, hepatocytes, coronary artery, spleen macrophages, and bone marrow macrophages, slight vacuolation in esophagus, submaxillary gland, cardiac muscle, aorta, lung macrophages, and thymus macrophages. Detected choroid plexus drug concentration of 30.233 mg/g, brain concentration of 18.7 μg/g, liver concentration of 1304 μg/g, and kidney concentration of 1092 μg/g after 35 days of dosing. Showed higher CSF concentration at 24 hours and significantly higher CSF/serum ratio at 24 hours on day 35 compared to day 1. |
|